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Question
Like other disorders with a strong genetic association, a
growing sequence dataset from various autoinflammatory
syndrome patients continues to identify many variants of
uncertain significance (VUS), i.e. missense and intronic
variants or small insertions/deletions, for which the impact
on protein function and pathways, and therefore the clini-
cal significance, is unknown. Since it is unclear how these
variants are associated with an increased risk of autoin-
flammatory disease, the clinical management of carriers of
VUS is complicated. Therefore, there is a strong demand
for reliable tests to rapidly assess the clinical significance
of VUS, providing carriers of these variants with the neces-
sary information to make an informed clinical decision
and refining treatment by stratified therapy strategies.
In many cases, a novel VUS is not common enough to
evaluate its significance. Common variants with appar-
ently variable penetrance can be more accessible as a
model to test functional aspects. A missense variant in
TNFRSF1A rs41495584 (“p.R92Q”) is the most com-
monly identified variant associated with TRAPS within
our mainly Caucasian UK patient population. The aim of
this study was to comprehensively examine the intracel-
lular signalling pathways that are affected by the presence
of p.R92Q, in comparison to normal cells and to well-
known symptomatic variants such as p.C33Y.
Methods
PBMCs were collected from patients and healthy volun-
teers with informed consent. Reverse-phase protein
microarray was applied to examine a large number of
signalling molecules and inflammatory cytokines, using
a feature subset selection process to identify distinctive
subsets.
Results
The resulting p.R92Q patient signatures demonstrated
that a particular range of inflammation-associated path-
ways were dysregulated in p.R92Q variant carriers,
grouping carriers together and readily distinguishable
from normal PBMCs and other known pathogenic
variants.
Conclusions
The inflammatory signaling pathways activated by the
TRAPS-associated variant p.R92Q are distinctive and
provide an opportunity to identify a strategy for correla-
tion of genetic findings and functional analysis. This is
applicable to straightforward or subtle phenotypes, and
common or rare genetic variants not only in TRAPS, but
also in other autoinflammatory diseases such as CAPS,
FMF, MKD, Blau syndrome and others. This represents
an important step towards genetic-bioinformatic disease
portraits with statistical and clinical relevance.
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